# EDGAR Filing Document

**Accession Number:** 0001231457
**File Stem:** 0001493152-26-011689
**Filing Date:** 2026-3
**Character Count:** 25842
**Document Hash:** 49e5794968afd0b639c1517034a73276
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-011689.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001493152-26-011689

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**EFFECTIVENESS DATE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENELUX Corp
- **CENTRAL INDEX KEY:** 0001231457
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294467
- **FILM NUMBER:** 26775306

**BUSINESS ADDRESS:**
- **STREET 1:** 2625 TOWNSGATE ROAD, SUITE 230
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361
- **BUSINESS PHONE:** 805-267-9889

**MAIL ADDRESS:**
- **STREET 1:** 2625 TOWNSGATE ROAD, SUITE 230
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENELUX CORP
- **DATE OF NAME CHANGE:** 20030508

**As filed with the Securities and Exchange Commission on March 19, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER THE SECURITIES ACT OF 1933***

**GENELUX CORPORATION**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **77-0583529** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(I.R.S. Employer<br> Identification No.)** |
| **2625 Townsgate Road, Suite 230**<br> **Westlake Village, California 91361** | **91361** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2022 Equity Incentive Plan**

**2022 Employee Stock Purchase Plan**

**(Full title of the plans)**

**Thomas Zindrick, J.D.**

**President and Chief Executive Officer**

**Genelux Corporation**

**2625 Townsgate Road, Suite 230**

**Westlake Village, California 91361**

**(805) 267-9889**

**(Name, address, and telephone number, including area code, of agent for service)**

***Copies to:***

**Jason L. Kent**

**Christine S. Kim**

**Cooley LLP**

**10265 Science Center Drive**

**San Diego, California 92121**

**(858) 550-6000**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (the "***Registration Statement***") is being filed by Genelux Corporation (the "***Registrant***") for the purpose of registering (i) an additional 1,906,957 shares of Registrant's common stock, par value $0.001 per share (the "***Common Stock***"), under the Registrant's 2022 Equity Incentive Plan (the "***2022 Plan***") pursuant to the provisions for the 2022 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 Plan and (ii) an additional 381,391 shares of Registrant's Common Stock under the Registrant's 2022 Employee Stock Purchase Plan (the "***2022 ESPP***" and together with the 2022 Plan, the "***Plans***") pursuant to the provisions for the 2022 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2022 ESPP, in each case on January 1, 2026.

Pursuant to General Instruction E of Form S-8, this Registration Statement incorporates by reference the contents of the registration statements on Form S-8 relating to the Plans filed by the Registrant with the Securities and Exchange Commission (the "***SEC***") on January 26, 2023 ([File No. 333-269427](https://www.sec.gov/Archives/edgar/data/1231457/000119312523016375/d356831ds8.htm)), March 29, 2024 ([File No. 333-278372](https://www.sec.gov/Archives/edgar/data/1231457/000149315224011949/forms-8.htm)) and March 28, 2025 ([File No. 333-286223](https://www.sec.gov/Archives/edgar/data/1231457/000164117225001209/forms-8.htm)) (collectively, the "***Prior Registration Statements***"), except that the provisions contained in Part II of such Prior Registration Statements are modified or supplemented, as the case may be, as set forth in this registration statement.

**PART II**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:

(a) the
 Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm) for the year ended December 31, 2025, filed with the SEC on March 19, 2026;

(b) the
 Registrant's Current Report on Form 8-K filed with the SEC on [January 2, 2026](http://www.sec.gov/Archives/edgar/data/1231457/000149315226000115/form8-k.htm) , [January 5, 2026](https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/form8-k.htm) , [January 8, 2026](https://www.sec.gov/Archives/edgar/data/1231457/000149315226000989/form8-k.htm) and [March 19, 2026](https://www.sec.gov/Archives/edgar/data/1231457/000149315226011649/form8-k.htm) (each to the extent the information in such reports is filed and not furnished); and

(c) the
 description of the Registrant's Common Stock contained in the Registrant's registration statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1231457/000119312523013085/d526802d8a12b.htm) , filed
 with the SEC on January 23, 2023, including any amendments or reports filed for the purpose of updating such description, including [Exhibit 4.16](https://www.sec.gov/Archives/edgar/data/1231457/000164117225001184/ex4-16.htm) of the Registrant's Annual Report on [Form 10-K](https://www.sec.gov/Archives/edgar/data/1231457/000164117225001184/form10-k.htm) for the year ended December 31, 2024, filed with the SEC on March
 28, 2025.

All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of exhibits furnished on such form that relate to items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**Item 8. Exhibits.**

The exhibits to this Registration Statement are listed below:

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the SEC on January 30, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000119312523019058/d389604dex31.htm) |
| 4.2 | [Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the SEC on January 30, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000119312523019058/d389604dex32.htm) |
| 4.3 | [Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-265828), filed with the SEC on August 29, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522232732/d300051dex41.htm) |
| 4.4 | [Form of Representative's Warrant (incorporated herein by reference to Exhibit 4.7 to the Amendment No. 2 of Form S-1(File No. 333-265828), filed with the SEC on September 19, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522246569/d300051dex11.htm) |
| 4.5 | [Form of Underwriter Warrant dated March 26, 2025 (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the SEC on March 25, 2025).](https://www.sec.gov/Archives/edgar/data/1231457/000164117225000642/ex4-1.htm) |
| 4.6 | [Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-41599), filed with the SEC on May 24, 2024).](https://www.sec.gov/Archives/edgar/data/1231457/000149315224021265/ex4-1.htm) |
| 5.1\* | [Opinion of Cooley LLP.](ex5-1.htm) |
| 23.1\* | [Consent of Weinberg & Company, P.A., independent registered public accounting firm.](ex23-1.htm) |
| 23.2\* | [Consent of Cooley LLP (included in Exhibit 5.1).](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on the signature page hereto).](#a_001) |
| 99.1 | [Genelux Corporation 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Registration Statement on Form S-1 (File No. 333-265828), as amended, filed with the SEC on January 10, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000119312523005002/d300051dex105.htm) |
| 99.2 | [Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Genelux Corporation 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Registration Statement on Form S-1 (File No. 333-265828), as amended, originally filed with the SEC on June 24, 2022).](https://www.sec.gov/Archives/edgar/data/1231457/000119312522181565/d300051dex106.htm) |
| 99.3 | [Genelux Corporation 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Registrant's Registration Statement on Form S-1 (File No. 333-265828), as amended, filed with the SEC on January 10, 2023).](https://www.sec.gov/Archives/edgar/data/1231457/000119312523005002/d300051dex107.htm) |
| 107\* | [Filing Fee Table.](ex107.htm) |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Westlake Village, State of California, on March 19, 2026.

---

| | |
|:---|:---|
| **GENELUX CORPORATION** | **GENELUX CORPORATION** |
| By: | */s/ Thomas Zindrick, J.D.* |
|  | Thomas Zindrick, J.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Thomas Zindrick, J.D. and Matthew Pulisic as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Thomas Zindrick, J.D.* | President, Chief Executive Officer and Chairman of the Board | March 19, 2026 |
| Thomas Zindrick, J.D. | (*Principal Executive Officer*) |  |
| */s/ Matthew Pulisic* | Chief Financial Officer | March 19, 2026 |
| Matthew Pulisic | (*Principal Financial and Accounting Officer*) |  |
| */s/ Mary Mirabelli* | Director | March 19, 2026 |
| Mary Mirabelli |  |  |
| */s/ James L. Tyree* | Director | March 19, 2026 |
| James L. Tyree |  |  |
| */s/ John Smither* | Director | March 19, 2026 |
| John Smither |  |  |
| */s/ John Thomas, Ph.D.* | Director | March 19, 2026 |
| John Thomas, Ph.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

Jason L. Kent

T: +1 858 550 6044

jkent@cooley.com

March 19, 2026

Genelux Corporation

2625 Townsgate Road, Suite 230

Westlake Village, California 91361

---

| | |
|:---|:---|
| **Re:** | **Genelux Corporation** |

---

Ladies and Gentlemen:

We have acted as counsel to Genelux Corporation, a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***"), covering the offering of up to 2,288,348 shares (the "***Shares***") of the Company's Common Stock, par value $0.001 per share ("***Common Stock***"), consisting of (i) 1,906,957 shares of Common Stock issuable pursuant to the Company's 2022 Equity Incentive Plan (the "***Incentive Plan***") and (ii) 381,391 shares of Common Stock issuable pursuant to the Company's 2022 Employee Stock Purchase Plan (together with the Incentive Plan, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the Plans, (c) the Company's certificate of incorporation and bylaws, each as currently in effect, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely

Cooley LLP

---

| | |
|:---|:---|
| By: | */s/ Jason L. Kent* |
|  | Jason L. Kent |

---

Cooley LLP 55 Hudson Yards New York, NY 10001<br> t: (212) 479-6000 f: (212) 479-6275 cooley.com

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 pertaining to Genelux Corporation 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan, of our report dated March 19, 2026, (which report contains an explanatory paragraph describing conditions that raise substantial doubt about Genelux Corporation's ability to continue as a going concern), relating to the financial statements of Genelux Corporation as of December 31, 2025 and 2024, which appear in Genelux Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission.

---

| |
|:---|
| /s/ Weinberg & Company, P.A. |
| Los Angeles, California |
| March 19, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **GENELUX Corp**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.001 per share, reserved for issuance pursuant to the 2022 Equity Incentive Plan | Other | 1906957 | $2.59 | $4939018.63 | 0.0001381 | $682.08 |
| 2 | Equity | Common Stock, par value $0.001 per share, reserved for issuance pursuant to the 2022 Employee Stock Purchase Plan | Other | 381391 | $2.21 | $842874.11 | 0.0001381 | $116.41 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $5781892.74  |  | $798.49  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $798.49  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> The amount registered represents shares of common stock, par value $0.001 per share ("common stock"), of Genelux Corporation (the "Registrant") that were automatically added to the shares authorized for issuance under the Registrant's 2022 Equity Incentive Plan (the "2022 Plan") on January 1, 2026, pursuant to an annual "evergreen" increase provision contained in the 2022 Plan. Pursuant to such provision, on January 1 of each year commencing in 2024, the number of shares authorized for issuance under the 2022 Plan is automatically increased by: (a) a number equal to 5% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year; or (b) a number determined by the Registrant's board of directors that is less than the amount set forth in the foregoing clause (a). Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the Registrant's 2022 Plan by reason of any stock dividend, stock split, recapitalization, or other similar transaction. The proposed maximum offering price per unit and maximum aggregate offering price are estimated in accordance with Rule 457(c) and 457(h)(1) of the Securities Act solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Capital Market on March 13, 2026 (the "Average Price").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> The amount registered represents shares of the Registrant's common stock that were automatically added to the shares authorized for issuance under the Registrant's 2022 Employee Stock Purchase Plan (the "2022 ESPP") on January 1, 2026, pursuant to an annual "evergreen" increase provision contained in the 2022 ESPP. Pursuant to such provision, on January 1 of each year commencing in 2024, the number of shares authorized for issuance under the 2022 ESPP is automatically increased by a number equal to the lesser of: (a) 1% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year; (b) 2,100,000 shares of Common Stock or (b) a number determined by the Registrant's board of directors that is less than the amount set forth in the foregoing clauses (a) and (b). Pursuant to Rule 416(a) promulgated under the Securities Act, this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2022 ESPP by reason of any stock dividend, stock split, recapitalization, or other similar transaction. The proposed maximum offering price per unit is estimated in accordance with Rule 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of the Average Price, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2022 ESPP.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---